相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management
Susan Branford et al.
BLOOD (2012)
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia
Naoto Takahashi et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials
Min Tang et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Standardized definitions of molecular response in chronic myeloid leukemia
N. C. P. Cross et al.
LEUKEMIA (2012)
Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response
Ho-Young Yhim et al.
LEUKEMIA RESEARCH (2012)
Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features
David M. Ross et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
Jan Kroenke et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay
Hyun-Gyung Goh et al.
LEUKEMIA & LYMPHOMA (2011)
In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib
Manuel Sobrinho-Simoes et al.
BLOOD (2010)
Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells
Toni Lenaerts et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia
Andreas Burchert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
D. M. Ross et al.
LEUKEMIA (2010)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy
David Grimwade et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha
Dushyant Verma et al.
LEUKEMIA & LYMPHOMA (2008)
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria
Susan Branford et al.
CLINICAL CANCER RESEARCH (2007)
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
Philippe Rousselot et al.
BLOOD (2007)
Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications
Ingo Roeder et al.
NATURE MEDICINE (2006)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy Hughes et al.
BLOOD (2006)
Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy
Jaspal Kaeda et al.
BLOOD (2006)
Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?
J Goldman et al.
LEUKEMIA & LYMPHOMA (2006)
Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation
T Lange et al.
LEUKEMIA (2005)
Dynamics of chronic myeloid leukaemia
F Michor et al.
NATURE (2005)
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program
J Gabert et al.
LEUKEMIA (2003)
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia
A Burchert et al.
BLOOD (2003)
Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa
FX Mahon et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
JJ Molldrem et al.
NATURE MEDICINE (2000)
分享论文
